Tango and Erasca Launch Pancreatic Cancer Trial
A Phase 1/2 study pairs Tango's vopimetostat with Erasca's ERAS-0015 in RAS-driven cancers now open for enrollment.
Updated on Nov. 4, 2026 in Cancer
Tango Therapeutics and Erasca announced on November 4, 2026, that a Phase 1/2 study of vopimetostat in combination with ERAS-0015 is open for enrollment. The trial targets MTAP-deleted pancreatic ductal adenocarcinoma and MTAP-deleted/RAS-mutant non-small cell lung cancer.
Why it matters
The combination pairs pan-RAS inhibition with PRMT5 inhibition, a targeted approach aimed at cancers that have few effective treatment options. Tango's CEO states that co-targeting PRMT5 and RAS is a promising new frontier in treating pancreatic cancer and potentially other RAS-driven cancers.
The trial is registered as NCT07897734 on clinicaltrials.gov, and ERAS-0015 showed partial responses at 8 mg once daily in the earlier AURORAS-1 study. Whether the combination will produce durable responses in patients remains unknown until dose-escalation data are reported.
The players
Tango Therapeutics
Tango Therapeutics is a Boston-based biotechnology company developing targeted cancer therapies, including the PRMT5 inhibitor vopimetostat.
Erasca
Erasca is a San Diego-based precision oncology company focused on developing treatments that target RAS-pathway cancers, including ERAS-0015.
The details
The open-label, multicenter dose-escalation and expansion trial evaluates the combination of vopimetostat, an oral once-daily PRMT5 inhibitor, and ERAS-0015, an oral pan-RAS molecular glue. Primary objective of the dose-escalation portion is to determine the maximum tolerated dose, with secondary objectives including antitumor activity, pharmacokinetics, safety, and tolerability.
Timeline
November 4, 2026: Study initiation announced and enrollment opened.
Health Landscape
The combination extends the earlier AURORAS-1 study of ERAS-0015, where partial responses were first observed at 8 mg once daily. Pairing pan-RAS inhibition with PRMT5 inhibition represents an attempt to address RAS-driven tumors that have resisted single-agent approaches.
Patients with MTAP-deleted pancreatic or RAS-mutant lung cancer may ask their oncologists whether enrollment in this trial is an option. The study is open now, but eligibility is determined by the trial's inclusion criteria, not by general availability.
The takeaway
Patients and clinicians tracking RAS-driven cancers should watch for dose-escalation results that determine the tolerable dose of this combination. Early-stage trials like this one can take years before any treatment reaches routine use.
Further reading
Explore more cancer treatment research coverage in the United States.
More information
Find full eligibility criteria in the clinicaltrials.gov listing for NCT07897734.
Source note: This article includes information reported by The Manila times.
